NavDx ® is the only Medicare-covered MRD test for HPV-positive Head & Neck and Anal Cancers Expands CareDx’s estimated addressable market...
Sharpens focus on U.S. precision medicine Testing Services and Patient & Digital Solutions
Growing body of evidence supports AlloSure ® as a clinical endpoint for risk assessment, treatment response, and long-term graft outcomes Data across...
AlloSure ® Kidney elevations are associated with increased risk of graft dysfunction and loss in kidney transplant recipients Data...
CareDx (NASDAQ:CDNA) executives outlined the company’s growth strategy, first-quarter performance and pipeline priorities during a presentation at the Jefferies Healthcare Conference, emphasizing transplant...
CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare...
CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare...
CareDx, Inc. (Nasdaq: CDNA), — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value...
Transaction extends CareDx’s Precision Medicine Testing Services strategy into specialty oncology with a Medicare-reimbursed commercial-stage MRD test and platform addressing a $4.5 Billion TAM ...